EuroBiotech: More Articles of Note

(Image: Pixabay)

> Ablynx dosed the first patient in a Japanese phase 2a trial of its treatment for respiratory syncytial virus. Data from the study are due in the second half of next year. Release 

> MyBiotics entered into another licensing agreement with Ferring. The deal covers microbiome therapies. Statement

> Artios Pharma in-licensed a DNA nuclease-targeting cancer drug. The asset is the first picked up by Artios through its research collaboration with Masaryk University in the Czech Republic. Release


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> A phase 2 trial of Sanfit’s treatment of calciphylaxis met its primary and secondary endpoints. The finding suggests SNF472 may aid wound healing and reduce pain in patients with the rare disease. Statement 

> BioMedPartners closed a CHF 100 million ($106 million) investment fund. The Swiss VC shop will use the money to back 12 to 15 early to midstage companies in its home country and neighboring nations. Release (PDF)

> Summit Therapeutics expanded enrollment in its phase 2 Duchenne muscular dystrophy trial. Enrollment is now open to patients who participated in the phase 1 study but fell foul of the more restrictive inclusion/exclusion criteria of the subsequent trial. Statement

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.